Incyte Acquires Vega Therapeutics for $1.25B Upfront

Incyte completed the acquisition of Vega Therapeutics for $1.25 billion upfront, adding Phase 3 VWD asset VGA039. This deal significantly strengthens the company's hematology pipeline with a potential first-in-class therapy.